NVSNovartis PharmaceuticalsFinished
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
Neuroendocrine Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 71 (final count)
- Started
- Mar 21, 2024
- Main results expected
- Dec 27, 2024
- Fully finished
- Dec 27, 2024
- Results posted
- Feb 3, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of [68Ga]Ga-DOTA-TATE Positive Participants (TP Participants) Among CIM Positive Participants (TP or FN Participants)
Measured over: Day 1
Number of [68Ga]Ga-DOTA-TATE Negative Participants (TN Participants) Among CIM Negative Participants (TN or FP Participants)
Measured over: Day 1
Subject-level Sensitivity
Measured over: Day 1
Subject-level Specificity
Measured over: Day 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06240741 · record last updated 2026-02-03 · checked 2026-11-09 15:47 UTC